Peptides for Acromegaly
Overview
3 research peptides are currently studied for acromegaly. This guide ranks them by evidence strength and covers their mechanisms, safety profiles, and current clinical status.
Octreotide — FDA Approved
Evidence Rating: A Category: Endocrine / Somatostatin Analog
Octreotide is a synthetic 8-amino-acid cyclic peptide (MW ~1019.2 g/mol) that mimics the pharmacological actions of natural somatostatin but with a significantly longer half-life. It was the first somatostatin analog approved by the FDA (1988) and is available as both an immediate-release subcutaneo...
Key claims: Controls symptoms and biochemical markers in acromegaly; Controls carcinoid syndrome symptoms.
Lanreotide — FDA Approved
Evidence Rating: A Category: Endocrine / Somatostatin Analog
Lanreotide is a synthetic 8-amino-acid cyclic somatostatin analog (MW ~1096.3 g/mol) available as a long-acting deep subcutaneous depot injection (Somatuline Depot/Autogel). It is FDA-approved for acromegaly and for the treatment of unresectable, well- or moderately-differentiated, locally advanced ...
Key claims: Controls GH and IGF-1 in acromegaly; Extends progression-free survival in GEP-NETs.
Pasireotide — FDA Approved
Evidence Rating: A Category: Endocrine / Somatostatin Analog
Pasireotide is a synthetic cyclohexapeptide somatostatin analog (MW ~1164.7 g/mol) with a unique broad somatostatin receptor binding profile, exhibiting high affinity for SSTR1, SSTR2, SSTR3, and SSTR5 (40-fold higher SSTR5 affinity than octreotide). It is FDA-approved for Cushing disease (Signifor ...
Key claims: Reduces urinary free cortisol in Cushing disease; Controls acromegaly in patients refractory to first-generation somatostatin analogs.